DeepMed Research

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

First-line Palbociclib and Endocrine Therapy for Patients With HR+/HER2- Advanced Breast Cancer in the Real-world Setting.

Active, not recruiting

Conditions: Breast Neoplasms

Interventions: Drug: Palbociclib + endocrine therapy

First Posted Date: 2021-02-23

Last Posted Date: 2025-03-10

Lead Sponsor: Pfizer

Target Recruit Count: 1443

Registration Number: NCT04767594

Locations: 🇩🇪
imland gGmbH, Fockbek, Germany
🇩🇪
Gemeinschaftspraxis für internistische Hämatologie und Onkologie, Rheine, Germany
🇩🇪
Nadler GmbH, Rinteln, Germany

and more 191 locations

STUDY OF PF-07321332 IN HEALTHY PARTICIPANTS

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: PF-07321332 Dose 2
Drug: PF-07321332 Dose 3
Drug: PF-07321332 Dose 4
Drug: PF-07321332 Dose 5
Drug: PF-07321332 Dose 4 or Placebo (Fed)
Drug: PF-07321332 Dose 1

First Posted Date: 2021-02-16

Last Posted Date: 2024-10-15

Lead Sponsor: Pfizer

Target Recruit Count: 70

Registration Number: NCT04756531

Locations: 🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium
🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States

Real World Data Collection Pediatric Neuroblastoma Treated With Lorlatinib

Terminated

Conditions: Neuroblastoma

Interventions: Drug: lorlatinib

First Posted Date: 2021-02-15

Last Posted Date: 2023-03-17

Lead Sponsor: Pfizer

Target Recruit Count: 15

Registration Number: NCT04753658

Locations: 🇳🇿
Starship Blood and Cancer Centre, Auckland, New Zealand
🇵🇹
Instituto Portugues de Oncologia de Lisboa, Lisboa, Portugal
🇸🇪
Queen Silvia Children's Hospital, Gothenburg, Sweden

and more 8 locations

Acute Respiratory Illness Surveillance (AcRIS) With Mobile Application in a Low-Interventional Decentralized Study.

Completed

Conditions: Healthy

Interventions: Diagnostic Test: SARS-CoV-2/Influenza/RSV RT-PCR

First Posted Date: 2021-02-10

Last Posted Date: 2024-02-23

Lead Sponsor: Pfizer

Target Recruit Count: 9151

Registration Number: NCT04748445

Locations: 🇺🇸
Ochsner Clinic Foundation, New Orleans, Louisiana, United States

Post Marketing Surveillance (PMS) Study of Cresemba in Korea.

Recruiting

Conditions: Aspergillosis
Mucormycosis

First Posted Date: 2021-02-09

Last Posted Date: 2023-03-13

Lead Sponsor: Pfizer

Target Recruit Count: 600

Registration Number: NCT04744454

Locations: 🇰🇷
Pfizer Korea, Seoul, Korea, Republic of

Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine

Phase 3

Recruiting

Conditions: Acute Treatment of Migraine

Interventions: Drug: Rimegepant (PF-07899801)

First Posted Date: 2021-02-08

Last Posted Date: 2025-05-25

Lead Sponsor: Pfizer

Target Recruit Count: 600

Registration Number: NCT04743141

Locations: 🇺🇸
Advanced Research Center, Inc., Anaheim, California, United States
🇺🇸
Perseverance Research Center, LLC, Scottsdale, Arizona, United States
🇺🇸
Physicians Research Group, Tempe, Arizona, United States

and more 109 locations

Study to Evaluate Overall Survival in Japanese Patients With HR+/HER2- Advanced Breast Cancer Treated With Palbociclib Plus Letrozole

Completed

Conditions: Breast Cancer

First Posted Date: 2021-02-03

Last Posted Date: 2024-04-04

Lead Sponsor: Pfizer

Target Recruit Count: 28

Registration Number: NCT04735367

Locations: 🇯🇵
Saitama Cancer Center, Kita-adachi-gun, Saitama, Japan
🇯🇵
National Hospital Organization Shikoku Cancer Center, Matsuyama, Ehime, Japan
🇯🇵
Kyoto University Hospital, Kyoto, Japan

and more 10 locations

Study to Evaluate Patient Reported Outcome (PRO) and Physical Activity in Japanese Patients With HR+/HER2- Advanced Breast Cancer Treated With Palbociclib Plus Endocrine Therapy or Endocrine Monotherapy

Not Applicable

Completed

Conditions: Breast Cancer

Interventions: Device: Wearable device

First Posted Date: 2021-02-03

Last Posted Date: 2024-11-22

Lead Sponsor: Pfizer

Target Recruit Count: 99

Registration Number: NCT04736576

Locations: 🇯🇵
Toranomon Hospital, Minato, Tokyo, Japan
🇯🇵
Saitama Cancer Center, Kita-adachi-gun, Saitama, Japan
🇯🇵
Hokkaido Cancer Center, Sapporo, Hokkaido, Japan

and more 17 locations

Expanded Access Protocol for Adults and Pediatric Patients With Sickle Cell Disease Who Have No Alternative Treatment Options

Conditions: Sickle Cell Disease

First Posted Date: 2021-01-26

Last Posted Date: 2024-11-20

Lead Sponsor: Pfizer

Registration Number: NCT04724421

Locations: 🇺🇸
Phoenix Children's Hospital, Phoenix, Arizona, United States
🇺🇸
Rady Children's Hospital San Diego, San Diego, California, United States
🇺🇸
Nemours/Alfred I. duPont Hospital for Children, Wilmington, Delaware, United States

and more 34 locations

A Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001)

Phase 2

Active, not recruiting

Conditions: Breast Cancer

Interventions: Drug: Tucatinib
Biological: Trastuzumab
Drug: Capecitabine

First Posted Date: 2021-01-25

Last Posted Date: 2025-05-28

Lead Sponsor: Pfizer

Target Recruit Count: 66

Registration Number: NCT04721977

Locations: 🇰🇷
Seoul National University Hospital ( Site 2003), Seoul, Korea, Republic of
🇯🇵
National Cancer Center Hospital ( Site 1003), Tokyo, Japan
🇯🇵
Fukushima Medical University Hospital ( Site 1012), Fukushima, Japan

and more 25 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy